A rat model of autism spectrum disorder (ASD), induced via prenatal valproic acid (VPA) exposure, received PEGylated liposomal resveratrol (LipRSV) from postnatal day 6–27. While LipRSV selectively reduced reactive oxygen species in the hippocampus, cerebellum, and posterior cortex, it failed to improve any behavioral outcomes across developmental milestones, olfactory discrimination, social interaction, or open-field tests. More critically, LipRSV suppressed BDNF and NGF levels across brain regions and induced behavioral deficits and redox imbalance even in healthy control animals — a troubling off-target toxicity signal.
The finding challenges a seductive assumption in neurotherapeutics: that antioxidant delivery alone can rescue complex neurodevelopmental phenotypes. ASD pathology involves not just oxidative stress but dysregulated synaptic pruning, mTOR signaling, GABAergic imbalance, and immune-neural crosstalk — none of which resveratrol's redox mechanism addresses. The BDNF and NGF suppression is particularly concerning, as both neurotrophins are already implicated in ASD pathophysiology and critical for early postnatal circuit refinement.
From a translational standpoint, the nanoparticle formulation itself may be introducing confounds — PEGylated liposomes are not biologically inert at therapeutic doses in developing brains. This is an early-stage animal study with n-limited groups, precluding clinical extrapolation. The result is nonetheless paradigm-clarifying: oxidative stress is likely a downstream consequence of ASD neurobiology, not a primary driver amenable to isolated correction. Future work must pair antioxidant strategies with neurotrophin-supportive or synaptic-stabilizing co-therapies.